Our understanding of AAV is increasing
AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases1,2
AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart.2
Read moreRecent updates
Kidney week – American Society of Nephrology 2020 (virtual)
Renal disease during maintenance treatment in ANCA associated vasculitis (AAV) remains a problem and glucocorticoid use is high
PosterCountry differences exist in the treatment of ANCA associated vasculitis (AAV but high dose and prolonged glucocorticoid use is observed across Europe
PosterGerman Congress of Rheumatology 2020
Maintenance treatment for ANCA-associated vasculitis (AAV) in real world practice in Germany - reality of vasculitis remission, relapse and burden of disease.
PosterEULAR 2020
Maintenance treatment for ANCA-associated vasculitis in real world practise in Europe – reality of vasculitis remission and relapse and significant burden of disease.
PresentationPatterns of drug treatment for maintenance phase of ANCA-associated vasculitis (AAV) in real world practise in Europe – prolonged glucocorticoid use is common and various treatment regimes are used.
PosterERA-EDTA 2020
Significant burden of disease during maintenance treatment of ANCA-associated vasculitis (AAV) patients in real world practice in Europe.
PosterRare Revolution Magazine – Special edition
The latest edition of Rare Revolution Magazine is dedicated exclusively to ANCA-associated vasculitis. Rare Revolution is a digital magazine giving a voice to patients affected by RARE conditions and the charities that represent and support them – you can view the May edition here.
Investigate AAV
Join the Rare Disease Investigation Team and put your expertise to the test in our interactive challenge. You’ll find it’s fully compatible with most desktop and mobile/tablet browsers (not for use on older versions of Internet Explorer or on Microsoft Edge).
Patient videos
View stories from Catherine, Jeremy, John & Susan and Shanali on the patient experience page.
Videos
Electronic consent form
You should only contact us if you are a HCP based outside of the US.
References & footnotes
AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis
Hutton HL, et al. Semin Nephrol 2017;37(5):418–35.
Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34.
Jennette JC, et al. Arthritis Rheum 2013;65(1):1–11.
Yates M, Watts R. Clin Med (Lond) 2017;17(1):60–4.
Pagnoux C. Eur J Rheumatol 2016;3(3):122–33.
ERA-EDTA 2019 | EULAR 2019
NEW materials to download
Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis. Poster >
High burden of disease for AAV patients in Germany - a claims study. Poster >
Economic burden of ANCA-associated vasculitis in Germany - a claims data study. Poster >
Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases. Poster >
Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data. Poster >
Renal damage in ANCA-associated vasculitis in incident and relapsing patients Slide deck >
ALSO NEW from UK Renal Week
Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients. Poster >
